Eris Lifesciences: Rating Boost Despite Missed Estimates

Published 10 months ago

Despite falling short of Bloomberg's projections, Eris Lifesciences saw a stock boost following Macquarie’s reaffirmed ‘Outperform’ rating and ₹1680 target price. The company demonstrated substantial YoY growth in profit, EBITDA, and revenue.

Macquarie maintains an ‘Outperform’ rating.
Revenue grew 28% year over year.
Profit increased 32% YoY.

You might like these

India Boosts LNG Import Capacity

IIFL Capital Sees Strong Q-o-Q Growth

Royal Enfield Sales Zoom 55%

India's Strong Economic Growth in FY2025

Prostarm's BESS Expansion Boosts India's Energy Market

Auto Retail Slips 4% in July: FADA

Axis Bank Q2 FY26 Highlights